MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.canlet.2026.218798

Медицинская библиотека · Cancer letters · 2026

Tertiary lymphoid structures in hepatocellular carcinoma: Prognostic biomarker, immunotherapy predictor, and emerging therapeutic target.

Bazar Mehriban, Tian Ye, Luan Haijing, Zhang Lin, Lu Qian, Wang Liang, Wang Xiaojuan, Dong Jiahong

СтатьяОбзорПеревод пока не подготовлен

Аннотация

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally, with many patients presenting with advanced disease that does not respond to standard treatments. While immune checkpoint inhibitors (ICIs) have improved outcomes, their effectiveness is limited in immunologically "cold" tumors, highlighting the urgent need to elucidate the complexity of the tumor immune microenvironment (TIME). Tertiary lymphoid structures (TLSs), ectopic and organized lymphoid aggregates that form at sites of chronic inflammation, have become key players in antitumor immunity. This review thoroughly covers the composition, multistage formation, and functional maturation of TLSs in HCC. We emphasize that the prognostic and predictive value of TLSs depends not only on their presence but also on their spatial localization, structural maturity, and specific immune cell composition. A high density of intratumoral TLSs (iTLSs), especially those with mature germinal centers containing B cells, T follicular helper (Tfh) cells, and dendritic cells (DCs), is strongly linked to better survival and lower recurrence rates. Additionally, TLSs serve as biomarkers for predicting favorable responses to ICIs in both neoadjuvant and adjuvant settings. We also explore how locoregional therapies and specific chemokine axes induce or modulate TLS formation. Finally, we discuss the emerging field of non-invasive TLS evaluation using radiomics and advanced imaging techniques, which promises to guide patient stratification for immunotherapy. TLSs therefore represent promising therapeutic targets with the potential to reprogram the immune milieu of HCC and enable more effective, personalized treatment approaches.

Для цитирования: Bazar Mehriban, Tian Ye, Luan Haijing, Zhang Lin, Lu Qian, Wang Liang, Wang Xiaojuan, Dong Jiahong. Tertiary lymphoid structures in hepatocellular carcinoma: Prognostic biomarker, immunotherapy predictor, and emerging therapeutic target.. Cancer letters. 2026. DOI: 10.1016/j.canlet.2026.218798.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.